{"disease":{"id":"papillary-renal-cell-carcinoma-type-2","name":"papillary renal cell carcinoma type 2"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02761057","title":"Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":152,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03177239","title":"Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":85,"lead_sponsor_name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","has_results":false},{"nct_id":"NCT01727089","title":"Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01688973","title":"Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03685448","title":"ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}